What is Wedbush's Estimate for Replimune Group Q3 Earnings?

Replimune Group, Inc. (NASDAQ:REPL - Free Report) - Equities researchers at Wedbush increased their Q3 2025 EPS estimates for Replimune Group in a research note issued on Tuesday, January 21st. Wedbush analyst R. Driscoll now anticipates that the company will earn ($0.63) per share for the quarter, up from their previous forecast of ($0.68). The consensus estimate for Replimune Group's current full-year earnings is ($2.91) per share. Wedbush also issued estimates for Replimune Group's Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.91) EPS, Q1 2026 earnings at ($0.69) EPS, Q2 2026 earnings at ($0.60) EPS, Q3 2026 earnings at ($0.42) EPS, Q4 2026 earnings at ($0.42) EPS, FY2026 earnings at ($2.37) EPS, FY2027 earnings at ($1.57) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.78) EPS.

Several other research analysts also recently weighed in on REPL. HC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the stock a "buy" rating in a research note on Wednesday. Jefferies Financial Group increased their target price on shares of Replimune Group from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, December 4th. Finally, BMO Capital Markets boosted their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Replimune Group currently has an average rating of "Buy" and a consensus target price of $19.14.

Replimune Group Stock Performance

NASDAQ REPL traded up $0.73 on Thursday, hitting $13.75. 1,186,336 shares of the stock traded hands, compared to its average volume of 925,546. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11. The business's fifty day moving average is $12.18 and its two-hundred day moving average is $11.28. Replimune Group has a 12 month low of $4.92 and a 12 month high of $17.00. The firm has a market capitalization of $940.78 million, a price-to-earnings ratio of -4.51 and a beta of 1.28.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.07.

Institutional Investors Weigh In On Replimune Group

Institutional investors have recently bought and sold shares of the stock. Point72 DIFC Ltd purchased a new position in shares of Replimune Group in the second quarter valued at about $57,000. Erste Asset Management GmbH purchased a new position in Replimune Group during the 3rd quarter valued at about $133,000. China Universal Asset Management Co. Ltd. raised its position in Replimune Group by 82.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock valued at $144,000 after purchasing an additional 5,926 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 81.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,011 shares of the company's stock worth $165,000 after buying an additional 6,748 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in shares of Replimune Group in the 3rd quarter worth approximately $222,000. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, insider Konstantinos Xynos sold 7,246 shares of Replimune Group stock in a transaction on Monday, November 18th. The shares were sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now owns 109,885 shares in the company, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the company's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $12.42, for a total transaction of $124,200.00. Following the sale, the chief executive officer now owns 202,014 shares of the company's stock, valued at approximately $2,509,013.88. The trade was a 4.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.